Exhibitors Search
CEFO Co., Ltd.
Booth no.
B61
|
Exhibition
|
|NextRegenX |
|---|---|
|
Country
|
| Korea, South |
|
Address
|
|45-13 Ujeongguk-ro, Jongno-gu, Seoul, Republic of Korea |
|
Tel
|
|+82-1032668573-- |
|
Exhibits
|
| Stem Cell-based Bone Regeneration Therapy and NK Cell Immunotherapy |
|
Company Type
|
| Biotech Venture / Startup |
Exhibitor Information
CEFOBio is a biotechnology venture founded on October 1, 2011, with the goal of researching and developing stem cell-based therapeutics.
We are currently conducting clinical trials for cell therapy products developed by differentiating stem cells into functional cells.
Our core technology is a three-dimensional differentiation technology that induces rapid differentiation of stem cells into osteoblasts by culturing stem cells under precisely controlled hydrogel stiffness. In 2023, this technology was certified by the Ministry of Health and Welfare of Korea as a New Excellent Technology (NET No. 204) for pharmaceutical applications.
CF-M801, an osteoblast product differentiated from umbilical cord-derived stem cells, was initially developed for the treatment of femoral head osteonecrosis. In a Phase 1 clinical trial conducted in patients with osteonecrosis, CF-M801 demonstrated its safety and efficacy as an allogeneic cell therapy with no significant immune response. In September 202
We are currently conducting clinical trials for cell therapy products developed by differentiating stem cells into functional cells.
Our core technology is a three-dimensional differentiation technology that induces rapid differentiation of stem cells into osteoblasts by culturing stem cells under precisely controlled hydrogel stiffness. In 2023, this technology was certified by the Ministry of Health and Welfare of Korea as a New Excellent Technology (NET No. 204) for pharmaceutical applications.
CF-M801, an osteoblast product differentiated from umbilical cord-derived stem cells, was initially developed for the treatment of femoral head osteonecrosis. In a Phase 1 clinical trial conducted in patients with osteonecrosis, CF-M801 demonstrated its safety and efficacy as an allogeneic cell therapy with no significant immune response. In September 202
Individual Exhibit/Technology Introduction (Detailed)
-
Product Name : STeMiN® Human Adipocyte Conditioned Media ExtractThis cosmetic product contains human adipose-derived stem cell conditioned medium, developed by CEFOBio through years of research and expertise in stem cell technology. CEFOBio has secured patents related to skin whitening, regeneration, wrinkle improvement, and immune response suppression. In accordance with MFDS guidelines, various toxicity and safety evaluations, including skin sensitization testing, have also been completed.
KYUNGYON EXHIBITION CORP.
